Advert - Allergan

For again successively failing to comply with an undertaking by continuing to claim that Vistabel/Botox was clinically more potent than Bocouture/Xeomin, Allergan was ruled in breach of the following clauses of the Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry.

Clause 25 - Failing to comply with an undertaking.

Allergan was also publicly reprimanded by the Code of Practice Appeal Board.